Company Profile
Janux Stock Price, News & Catalysts
- Ticker:
- JANX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
18.60 USD (+6.96%)
Close
Last updated: August 24, 2026
840M USD
Market cap
Why the stock is moving
As of Aug 24, 2026, JANX closed up 6.96% at $18.60. No new same-company headline was identified in the current news window.
Company overview
Business overview
Janux Therapeutics is a precision-oncology company developing conditional T-cell engager therapies. Its platform aims to improve tumor targeting while limiting off-tumor toxicity.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Janux sits in specialty oncology biotechnology.
Business Model Characteristics
The company depends on clinical data, platform validation, and the possibility of creating a differentiated immuno-oncology franchise.
Position Within the Biotechnology Landscape
Janux is a platform oncology name with meaningful upside if its conditional-engager science continues to validate.
Future catalysts
- Janux's catalysts are PSMA and EGFR T-cell engagers, especially JANX007 and the next clinical updates. The company remains highly event-driven.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Janux (JANX)?
Janux (JANX) most recently closed at 18.60 USD, a +6.96% move versus the previous session.
What is the market cap of Janux (JANX)?
Janux currently has a market capitalization of 840M USD on BioPharmSignal.
What does Janux do?
Janux Therapeutics is a precision-oncology company developing conditional T-cell engager therapies. Its platform aims to improve tumor targeting while limiting off-tumor toxicity.
On which exchange is JANX stock listed?
Janux (JANX) is associated with NASDAQ, United States, Biopharma.
What is Janux?
Janux's catalysts are PSMA and EGFR T-cell engagers, especially JANX007 and the next clinical updates.
Which conditions is Janux targeting with Janux?
Janux is associated with oncology based on its company overview and current catalyst commentary.
How does Janux describe recent progress with Janux?
Janux's catalysts are PSMA and EGFR T-cell engagers, especially JANX007 and the next clinical updates.
What is Therapeutics?
Janux Therapeutics is a precision-oncology company developing conditional T-cell engager therapies.